Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 55

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 55
---
 market for the product candidate, the costs and complexities
of manufacturing and delivering the product to patients and the potential of competing products. The partner may also consider alternative
product candidates or technologies for similar indications that may be available for collaboration and whether such collaboration could
be more attractive than the one with us for our product candidate.

These agreements are complex
and time consuming to negotiate and document. Further, there have been a significant number of recent business combinations among large
pharmaceutical companies that have resulted in a reduced number of potential future licensing and collaboration partners.

We may not be able to negotiate
agreements with these potential partners on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to
curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one
or more of our other development programs.

If we enter into agreements with a licensing or collaboration partner for the development and commercialization of our product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those collaborations.

We expect a material amount
of our revenue in the future will be derived from licensing or collaboration agreements with other biopharmaceutical companies, research
institutes and universities and similar agreements. We may enter into additional agreements with a licensing or collaboration partner
for the development and commercialization of certain of our product candidates. If we enter into such agreements, we will have limited
control over the amount and timing of resources that our partners will dedicate to the development or commercialization of our product
candidates. Our ability to generate revenues from these arrangements will depend on any future licensing partners’ ability to successfully
perform the functions assigned to them in these arrangements. In addition, any future licensing or collaboration partner may have the
right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon
the expiration of the agreed upon terms.

Agreements involving our product
candidates pose a number of risks, including:

| • | partners have significant discretion in determining the efforts and resources that they will apply to 
 these matters;                                                                                        |

| • | partners may not perform their obligations as expected; |

| • | partners may not pursue development and commercialization of our product candidates or may elect not to                                     
 continue or renew development or commercialization programs, based on clinical trial results, changes in their strategic focus or available 
 funding or external factors, such as an acquisition, that divert resources or